Padmanee Sharma
A5071033599- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Bladder and Urothelial Cancer Treatments
- CAR-T cell therapy research
- Immune cells in cancer
- Immune Cell Function and Interaction
- Viral Infections and Immunology Research
- Peptidase Inhibition and Analysis
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Nonmelanoma Skin Cancer Studies
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Genetic factors in colorectal cancer
- Adenosine and Purinergic Signaling
- Acute Myeloid Leukemia Research
- Cytokine Signaling Pathways and Interactions
- Lung Cancer Treatments and Mutations
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- Cancer, Lipids, and Metabolism
- Ear and Head Tumors
- Estrogen and related hormone effects
- Salivary Gland Tumors Diagnosis and Treatment
- T-cell and B-cell Immunology
The University of Texas MD Anderson Cancer Center
2016-2025
Scripps MD Anderson Cancer Center
2015-2024
Parker Institute for Cancer Immunotherapy
2017-2024
Spanish Oncology Genitourinary Group
1996-2023
The University of Texas Health Science Center at Houston
2014-2019
Memorial Sloan Kettering Cancer Center
2006-2018
Tennessee Oncology
2017-2018
Sarah Cannon
2017-2018
Yale Cancer Center
2018
Cornell University
2018
Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab everolimus carcinoma who had received previous treatment.
Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma a pilot study. This phase 3 trial compared nivolumab sunitinib for previously untreated clear-cell carcinoma.
Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined oral and of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy (
The recent advent of methods for high-throughput single-cell molecular profiling has catalyzed a growing sense in the scientific community that time is ripe to complete 150-year-old effort identify all cell types human body. Human Cell Atlas Project an international collaborative aims define terms distinctive profiles (such as gene expression profiles) and connect this information with classical cellular descriptions location morphology). An open comprehensive reference map state cells...
Early-phase trials targeting the T-cell inhibitory molecule programmed cell death ligand 1 (PD-L1) have shown clinical efficacy in cancer. This study was undertaken to determine whether PD-L1 is overexpressed triple-negative breast cancer (TNBC) and investigate loss of PTEN as a mechanism regulation. The Cancer Genome Atlas (TCGA) RNA sequencing data showed significantly greater expression gene TNBC (n = 120) compared with non-TNBC 716; P < 0.001). Breast tumor tissue microarrays were...
Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features pretreatment tumor biopsies have been reported to correlate with response patients melanoma other cancers, but robust biomarkers identified. We studied cohort of metastatic initially treated cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) (n = 53) followed by programmed death-1 (PD-1) at progression 46), analyzed signatures longitudinal tissue...
The molecular underpinnings that drive the heterogeneity of KRAS-mutant lung adenocarcinoma are poorly characterized. We performed an integrative analysis genomic, transcriptomic, and proteomic data from early-stage chemorefractory identified three robust subsets dominated, respectively, by co-occurring genetic events in STK11/LKB1 (the KL subgroup), TP53 (KP), CDKN2A/B inactivation coupled with low expression NKX2-1 (TTF1) transcription factor (KC). further revealed biologically...
Immune checkpoint blockade produces clinical benefit in many patients. However, better biomarkers of response are still needed, and mechanisms resistance remain incompletely understood. To address this, we recently studied a cohort melanoma patients treated with sequential against cytotoxic T lymphocyte antigen-4 (CTLA-4) followed by programmed death receptor-1 (PD-1) identified immune markers resistance. Building on these studies, performed deep molecular profiling including cell receptor...
Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer, but effect of diet and supplements on this interaction is not well studied. We assessed fecal microbiota profiles, dietary habits, commercially available probiotic supplement use melanoma patients performed parallel preclinical studies. Higher fiber was associated with significantly improved progression-free survival 128 ICB, most pronounced benefit observed sufficient intake no use. Findings were...
Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction cancers. We assessed the safety and efficacy nivolumab plus ipilimumab Western chemotherapy-refractory